Company News: Forest Labs, Almirall, Johnson & Johnson and Ethicon

Share this article:
Forest Labs entered a collaboration with Almirall to develop, market and distribute Almirall's LAS100977, a Phase II long-acting beta2 agonist, in the US. LAS100977 expands Forest's respiratory pipeline for COPD and marks the second such agreement between the firms. Three years ago, they teamed up on Eklira (aclidinium bromide), which is in Phase III for COPD.

Johnson & Johnson operating company Ethicon said it is acquiring Acclarent, a privately held maker of minimally-invasive devices used in sinus surgery, for $785 million in cash. In a statement, J&J said the acquisition of Acclarent gives Ethicon a new growth platform in ENT-related conditions. The transaction is expected to close in the first quarter of 2010.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.